A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma
The purpose of this study is to assess the safety of SyB L-0501 in combination with Rituximab to patients with aggressive B-cell non-Hodgkin's lymphoma, and to explore the recommended dose for the Phase II clinical trial.
Non-Hodgkin's Lymphoma|Diffuse Large B-Cell Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma
DRUG: SyB L-0501|DRUG: Rituximab
Dose-limiting toxicity, Treatment period
CR rate and the overall response rate, determination by Independent Review Committee, Treatment period
The purpose of this study is to assess the safety of SyB L-0501 in combination with Rituximab to patients with aggressive B-cell non-Hodgkin's lymphoma, and to explore the recommended dose for the Phase II clinical trial.